CN114768012B - Automatic quantitative drug delivery device for synchronous nasal cavity during exhalation - Google Patents
Automatic quantitative drug delivery device for synchronous nasal cavity during exhalation Download PDFInfo
- Publication number
- CN114768012B CN114768012B CN202210063868.0A CN202210063868A CN114768012B CN 114768012 B CN114768012 B CN 114768012B CN 202210063868 A CN202210063868 A CN 202210063868A CN 114768012 B CN114768012 B CN 114768012B
- Authority
- CN
- China
- Prior art keywords
- piston
- nasal cavity
- drug delivery
- delivery device
- butt joint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003928 nasal cavity Anatomy 0.000 title claims abstract description 52
- 238000012377 drug delivery Methods 0.000 title claims abstract description 35
- 230000001360 synchronised effect Effects 0.000 title claims abstract description 24
- 238000013461 design Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 63
- 229940079593 drug Drugs 0.000 claims description 31
- 230000004087 circulation Effects 0.000 claims description 16
- 210000001503 joint Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 210000000214 mouth Anatomy 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 230000001276 controlling effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 206010028748 Nasal obstruction Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 238000001990 intravenous administration Methods 0.000 abstract description 5
- 238000010253 intravenous injection Methods 0.000 abstract description 4
- 229940121657 clinical drug Drugs 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract 1
- 229940043263 traditional drug Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 9
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 8
- 229940093265 berberine Drugs 0.000 description 8
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000004081 cilia Anatomy 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 5
- 210000003300 oropharynx Anatomy 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000003836 berberines Chemical class 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000025938 nasal cavity disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0618—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention relates to an automatic quantitative drug delivery device for an expiration synchronous nasal cavity, which comprises: the drug delivery device is characterized in that the drug delivery device is integrally connected with all components by using an integrated wearing type design, and the components can be detached and replaced by using modularized combination. The automatic quantitative nasal cavity expiration synchronous drug delivery device overcomes the defects and the shortcomings of the traditional drug delivery device, has the advantages of automatic operation, safety, high efficiency and realization of constant-dose and long-time nasal cavity drug delivery effect similar to an intravenous drip mode, and meets the urgent need of clinical drug treatment of patients who are not suitable for intravenous injection.
Description
Technical Field
The invention relates to a nasal cavity drug delivery device, in particular to an automatic quantitative drug delivery device for a synchronous exhalation nasal cavity.
Background
The nasal cavity breathing zone is the largest part in the nasal cavity, has abundant submucosal blood vessels, and small veins, arterioles, capillaries and lymphatic vessels are interwoven into a net, so that the medicine can be rapidly absorbed, and the medicine can be absorbed into the systemic blood circulation, thereby improving the bioavailability of the medicine and avoiding the first pass effect of the oral medicine. In addition, the medicine which is not easy to absorb and is easy to be destroyed by gastric acid in the gastrointestinal tract can be effectively absorbed by the nasal mucosa, thereby improving the treatment effect of the medicine.
The nasal submucosa blood vessel is very abundant, arteries, veins and capillaries are interwoven into a net shape, the liquid medicine can be rapidly absorbed into the systemic circulation, and the absorption speed and the absorption degree can be sometimes equivalent to those of intravenous injection. However, the existing nasal formulations suffer from the following disadvantages:
1. the patient needs to be trained to grasp the administration procedure. Although the patient can self-apply the nasal administration preparation, there are few patients who need to be able to properly handle the nasal administration preparation.
2. When inhalation is needed, the administration is favorable for the medicine to enter the nasal cavity, but the medicine cannot be controlled to enter the lung through the oropharynx, so that the loss is caused.
3. The retention time in the nasal cavity is short, and in order to prolong the retention time, an adhesive is usually added, but the adhesive has serious influence on the activity of cilia in the nose, and has the problem of toxicity of the cilia.
4. Nasal formulations are often manually administered in a single dose, and cannot be administered in a constant dose, long-term "intravenous drip" like mode.
At present, the incidence rate of chronic diseases is increasing, and some chronic disease patients need multiple injection treatment, and repeated injection not only generates great psychological burden on the patients, but also can cause the problems of venous sinus, phlebitis and the like, so that the limb veins of the patients are free from pricking. In addition, the injection administration needs to be operated by a professional nurse, and the patient cannot administer the drug by himself, so that development of a nasal cavity administration device which is operated autonomously, safe and efficient, realizes a constant dose and is similar to an intravenous drip mode for a long time is needed. At present, reports of the device are not yet seen, so that the urgent need of clinical drug treatment of patients unsuitable for intravenous injection cannot be met.
Disclosure of Invention
The invention aims to provide the automatic quantitative drug delivery device for the synchronous expiration and nasal cavity, which is safe, efficient, quantitative and capable of delivering drugs for a long time.
The automatic quantitative nasal cavity expiration and synchronization drug delivery device has the following advantages of distinguishing the existing nasal cavity drug delivery device:
1. the safety is high: the medicine does not need to be added with adhesives with cilia toxicity (cilia fall-off caused by cilia swing inhibition), mucous membrane absorption promoters with potential safety and other additives, has no influence on physiological microenvironment of nasal cavity and cilia movement, has no side effects such as stimulation and the like, and has high safety.
2. Accurate positioning and high medicine utilization rate: the medicine is not required to be prepared into a special dosage form or special carriers are not required to be applied; the drug can be positioned and efficiently released only by preparing the drug into solution, emulsion and suspension, the drug can not enter the trachea and the lung, and the utilization rate is high.
3. Quick acting: the medicine has high dispersivity in the solution, small surface tension, high affinity with nasal mucosa, maximum acceleration of medicine absorption and fast acting.
4. Autonomous administration, convenient operation: the user adjusts the tension adjusting knob and the piston clip adjusting knob of the spring according to the self condition and the dosage of the drug, and the quantitative delivery of the drug to the nasal cavity can be completed through normal inhalation and exhalation. As shown in fig. 3-4, the application principle of the automatic quantitative drug delivery device for the synchronous nasal cavity of expiration is as follows: (1) When the oral cavity is inhaled, under the combined action of the inhalation and the tension spring, the pistons at the two sides move downwards, and the medicine flows into the quantifying chamber from the medicine butt joint pipe, and meanwhile, the medicine does not enter the nasal cavity due to the closing of the unidirectional flow port of the nasal cavity butt joint pipe. (2) When the mouth inhales at the tail end, the piston in the dosing chamber is blocked by the piston clamp to stop moving, and meanwhile, air enters from the outside through the air passage of the piston at the other side, so that the subsequent inhalation of a user is ensured. (3) When the oral cavity exhales, under the action of the pushing of the exhaling, the two side piston moves upwards, the medicine flows to the nasal cavity butt joint pipe from the quantifying chamber through the unidirectional flow port, meanwhile, as the unidirectional flow port of the medicine butt joint pipe is closed, no medicine enters the quantifying chamber (4) when the piston in the quantifying chamber moves to the bottom of the quantifying chamber, the movement is stopped, and the exhaling of the oral cavity flows out to the outside through the air passage of the piston at the other side, so that the exhaling smoothness is ensured. (5) When the oral cavity inhales again, the above processes (1) to (4) are repeated.
5. Achieving a constant dose and long-term nasal administration like "intravenous drip" mode: the automatic quantitative nasal cavity expiration and synchronous drug delivery device has the advantages that the drug enters the nasal cavity in a small-dose repeated administration mode, the full contact and absorption of nasal mucosa are ensured, the bioavailability of the drug is high, and the constant-dose long-time nasal cavity administration similar to an intravenous drip mode can be realized.
6. Patients do not need special operation requirements, and applicable crowds are wider: the drug delivery device of the invention is easy to realize autonomous drug delivery, has no pain or stimulation, is suitable for patients who are not suitable for long-term intravenous injection, and is also suitable for children, the elderly, patients with mental retardation and the like.
Drawings
Fig. 1 is a schematic diagram of the various components of an breath-synchronized nasal autonomous dosing drug delivery device of the present invention.
Fig. 2 is a schematic design structure of the automatic quantitative drug delivery device for the synchronous exhalation and nasal cavity of the invention.
Fig. 3 is a schematic diagram of the operation of the device for automatic quantitative drug delivery by synchronizing exhalation and nasal cavity during oral inhalation.
Fig. 4 is a schematic diagram of the operation of the device for automatic quantitative drug delivery by synchronizing the exhalation and nasal cavity during the exhalation of the oral cavity.
Detailed Description
Hereinafter, specific embodiments of the present invention will be described in detail. It should be noted that the technical features or combinations of technical features described in the following embodiments should not be regarded as being isolated, and they may be combined with each other to achieve a better technical effect.
As shown in fig. 1 to 4, the automatic quantitative drug delivery device for the synchronous exhalation nasal cavity of the present invention comprises: the dosing chamber 10, the device outer wall structure 11, the double-sided piston 20, the piston push-pull rod 21, the adjustable tension spring 30, the spring tension adjusting knob 31, the piston card 40, the piston card adjusting knob 41, the butt joint pipe 50, the unidirectional flow port 60, the bidirectional flow port 61 and the middle nasal obstruction 70 are integrally connected by using an integrated wearing type design, and the components are combined in a modularized mode, so that the dosing device can be detached and replaced, and is used for delivering liquid, solid or gaseous medicines.
The docking tube 50 includes: drug interface tube 51, nasal interface tube 52, and oral interface tube 53 for delivery of a drug or an air stream.
The dosing chamber 10 is connected with two unidirectional flow ports 60, and then is respectively connected with the drug docking tube 51 and the nasal docking tube 52, so that the drug is controlled to be delivered from the drug docking tube 51 to the dosing chamber 10 and then from the dosing chamber 10 to the nasal docking tube 52.
The outer wall structure 11 of the device is connected with a one-way circulation port 60 and two-way circulation ports 61, one two-way circulation port 61 is positioned at the top of the outer wall structure 11 of the device to provide an air flow inlet and outlet passage for the movement of the piston in the outer wall structure 11 of the device, the other two-way circulation port 61 is connected with the connecting pipe 53 to provide a passage for the air flow of oral breathing into and out of the outer wall structure 11 of the device, and one-way circulation port 60 is positioned in the middle of the outer wall structure 11 of the device to provide an air flow inlet passage for the movement of the piston to the position of the piston card 40 during the inhalation.
The piston push-pull rod 21 is connected with the double-sided piston 20, so that synchronous movement of the double-sided piston 20 is ensured; one side of the double-sided piston 20 is positioned in the dosing chamber 10 and used for controlling the medicine in the dosing chamber 10, the other side of the double-sided piston is positioned in the outer wall structure 11 of the device, and an air passage is arranged in the piston and is combined with a one-way circulation port 60 and a two-way circulation port 61 on the outer wall structure 11 of the device and used for regulating and controlling the progress of the double-sided piston 20 during oral inhalation and exhalation.
The adjustable tension spring 30 is connected with the piston push-pull rod 21 to provide auxiliary power for the piston in the quantitative chamber 10 to move downwards to the position of the piston clamp 40 in the air suction process; the spring tension adjusting knob 31 is connected with the adjustable tension spring 30 and is used for adjusting the tension of the adjustable tension spring 30.
The piston card 40 is connected with a piston card regulating knob 41 for controlling the volume of the medicine in the dosing chamber 10.
The hollow plug 70 includes a hollow passage therein for connecting the nasal interface tube 52 for delivering medication into the nasal cavity.
The middle nasal plug 70 is connected with the atomizer nozzle to disperse the medicine into tiny liquid drops, particles or aerosol, increase the surface area of the medicine and improve the absorption efficiency of the nasal cavity.
An application method of an automatic quantitative drug delivery device for a synchronous nasal cavity during expiration comprises the following steps:
(1) According to the self condition of the user and the dosage of the medicine, the spring tension regulating knob 31 and the piston card regulating knob 41 are regulated, the middle-through nasal plug 70 is plugged into the nasal cavity of the user, and the nasal cavity air inlet and outlet are completely blocked after the hollow channel of the middle-through nasal plug 70 is regulated to be at the position;
(2) The user maintains a stationary state, and performs normal inhalation and exhalation through the oral cavity to the mouthpiece 53, completing the quantitative delivery of the drug to the nasal cavity.
Example 1 test grouping of an exhalation-synchronized nasal autonomous quantitative drug delivery device
The synchronous exhalation nasal cavity autonomous quantitative drug delivery device provided by the invention is used for the following test.
The test person: the nasal cavity disease is avoided between the ages of 20 and 50, and the sex is unlimited.
The testing method comprises the following steps: the experimental group and the control group were each divided into 6 according to the design of Table 1, and 5mL of an aqueous berberine solution (10 mg/mL) was prepared using berberine as a drug representative. According to the self condition of the tester, the spring tension adjusting knob and the piston card adjusting knob are adjusted, so that the effective use of the automatic quantitative drug delivery device for the synchronous nasal cavity of expiration is ensured.
The experimental groups were dosed according to the application method of the invention according to the design of table 1, maintaining the posture for 10min after the end of the dosing. The control group was given nasal administration according to the design of table 1 with simultaneous reference to the experimental group method.
Example 2 test results of an expiration synchronous nasal autonomous quantitative drug delivery device
After nasal administration according to the design of table 1, the degree of retention of each group of drugs in the nasal cavity, nasal feeling and acceptability of the test subjects, bitter taste in the oropharynx, berberine concentration in plasma, and the like were evaluated.
Oropharyngeal sensation: the drug entering the nasal cavity was evaluated for its taste to the oropharynx by the perception of bitterness of the oropharynx.
Detection of berberine concentration in plasma: reference methods [ cuu, line Li Jiachuan, meng Xianli. Methodology for determining the concentration of 5 berberine alkaloids in plasma by HPLC. Third national institute of advanced technology, traditional Chinese medicine, modern International Association ], plasma samples were deproteinized with acetonitrile and then subjected to HPLC determination, comparing the levels of berberine concentrations in plasma of each group of testers at 5min post administration.
The test results of each group are shown in Table 2, the effect of each index in the table is expressed by 1-100 (the higher the numerical value is, the better the representative effect is), each index is synthesized, and the overall evaluation is given and is classified into 4 grades: excellent, good, medium, poor.
TABLE 1 test packets for synchronous exhalation nasal autonomous quantitative drug delivery device
Annotation: and/represents that the feature or structure is not present; * Indicating a significant difference in this component compared to the experimental group.
TABLE 2 test results of synchronous exhalation nasal autonomous quantitative drug delivery device
The results in table 2 show that the effects of the experimental group of the device for automatically and quantitatively delivering drugs through the synchronous exhalation and nasal cavity are obviously higher than those of the control group, and the device has the advantages of high retention degree of drugs in the nasal cavity, good nasal feeling, no bitter taste in the oropharynx and high concentration of berberine in blood plasma, and is good in overall evaluation, wherein the evaluation of the experimental group 2 is better.
Compared with the experimental group, the control group has poor effect, the control groups 1, 2, 7 and 9 to 11 have low or no berberine concentration in blood plasma, the administration effect is worst, various problems exist when the control groups 3 to 5 are applied, and the drugs entering the nasal cavity of the control group 8 have overflow leakage, so that the concentration of berberine in blood plasma is influenced.
The results in table 2 prove that any component and parameter in the technical protection scheme of the automatic quantitative drug delivery device for the synchronous exhalation nasal cavity are mutually synergistic and indispensable, and the lack of any component and parameter in the technical protection scheme can greatly influence the blood absorption effect of the drug. The automatic quantitative drug delivery device for the synchronous expiration and nasal cavity has the characteristics of safety, high efficiency and convenience in application, and has good application prospect.
The foregoing detailed description is directed to embodiments of the invention which are not intended to limit the scope of the invention, but rather to cover all modifications and variations within the scope of the invention. Further, various modifications, additions and substitutions in other forms and details may be made by those skilled in the art within the scope and spirit of the invention as disclosed in the accompanying claims. Of course, such modifications, additions and substitutions are intended to be included within the scope of the invention as set forth in the accompanying claims.
Claims (3)
1. The synchronous nasal cavity of exhaling is from quantitative drug delivery device, its characterized in that, drug delivery device include: the quantitative chamber and the outer wall structure of the device, double-side pistons and piston push-pull rods, an adjustable tension spring, a spring tension adjusting knob, a piston clamp adjusting knob, an opposite connection pipe, a one-way circulation port, a two-way circulation port and a middle nasal obstruction; the butt joint pipe includes: the medicine butt joint pipe, the nasal cavity butt joint pipe and the oral cavity butt joint pipe are used for conveying medicines or air flow; the quantitative chamber is connected with two unidirectional flow ports, then is respectively connected with the medicine butt joint pipe and the nasal cavity butt joint pipe, controls the medicine to be conveyed from the medicine butt joint pipe to the quantitative chamber, and then is conveyed from the quantitative chamber to the nasal cavity butt joint pipe; the device outer wall structure is connected with a one-way circulation port and two-way circulation ports, one two-way circulation port is positioned at the top of the device outer wall structure and provides an air flow access passage for the movement of a piston in the device outer wall structure, the other two-way circulation port is connected with an oral cavity butt joint pipe and provides a passage for the oral cavity respiratory air flow to enter and exit the device outer wall structure, and the one-way circulation port is positioned in the middle of the device outer wall structure and provides an air flow access passage for the movement of the piston to a piston clamping position in the air suction process; the piston push-pull rod is connected with the double-side pistons, so that synchronous movement of the double-side pistons is ensured; one side piston of the double-side piston is positioned in the quantitative chamber and used for controlling the medicine in the quantitative chamber to enter and exit, the other side piston is positioned in the outer wall structure of the device, an air passage is arranged in the piston, and the double-side piston is combined with a one-way circulation port and a two-way circulation port on the outer wall structure of the device and used for regulating and controlling the double-side piston process during oral inhalation and exhalation; the adjustable tension spring is connected with the piston push-pull rod and provides auxiliary power for the piston in the quantitative chamber to move downwards to the piston clamping position in the air suction process; the spring tension regulating knob is connected with the adjustable tension spring and is used for regulating the tension of the adjustable tension spring; the piston clamp is connected with the piston clamp regulating knob and is used for controlling the volume of the medicine in the quantitative chamber; the drug delivery device is characterized in that the components are connected into a whole by using an integrated wearable design, the components are combined in a modularized mode and can be detached and replaced, and the drug delivery device is used for delivering liquid, solid or gaseous drugs.
2. The device for automatically and quantitatively delivering drugs through the nasal cavity with synchronous expiration according to claim 1, wherein the hollow nasal plug comprises a hollow channel for connecting a nasal cavity butt joint pipe and delivering drugs into the nasal cavity.
3. The device for automatically and quantitatively delivering drugs through the nasal cavity with synchronous expiration according to claim 1, wherein the middle nasal plug is connected with an atomizer nozzle and is used for dispersing drugs into fine liquid drops, particles or aerosol, increasing the surface area of the drugs and improving the absorption efficiency of the nasal cavity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210063868.0A CN114768012B (en) | 2022-01-14 | 2022-01-14 | Automatic quantitative drug delivery device for synchronous nasal cavity during exhalation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210063868.0A CN114768012B (en) | 2022-01-14 | 2022-01-14 | Automatic quantitative drug delivery device for synchronous nasal cavity during exhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114768012A CN114768012A (en) | 2022-07-22 |
| CN114768012B true CN114768012B (en) | 2024-03-15 |
Family
ID=82422751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210063868.0A Active CN114768012B (en) | 2022-01-14 | 2022-01-14 | Automatic quantitative drug delivery device for synchronous nasal cavity during exhalation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114768012B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5755221A (en) * | 1990-09-12 | 1998-05-26 | Bisgaard; Hans | Aerosol inhaler with piston dump |
| US6752147B1 (en) * | 1998-01-30 | 2004-06-22 | Hagepharm Gmbh | Inhalation apparatus for powder medications |
| CN1524001A (en) * | 2001-02-26 | 2004-08-25 | ���յ�ŵ˹��˾ | Nasal devices |
| CN110464922A (en) * | 2019-08-19 | 2019-11-19 | 丁瑞芬 | A kind of vaporizer dose control equipment |
| WO2021150883A1 (en) * | 2020-01-22 | 2021-07-29 | Virginia Commonwealth University | Air-jet dry power inhaler for rapid delivery of pharmaceutical aerosols to infants |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060289006A1 (en) * | 2005-06-27 | 2006-12-28 | Kos Life Sciences, Inc. | Breath actuated nasal drug delivery system |
| WO2008122018A1 (en) * | 2007-04-02 | 2008-10-09 | Abbott Respiratory Llc | Breath actuated nasal pump |
-
2022
- 2022-01-14 CN CN202210063868.0A patent/CN114768012B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5755221A (en) * | 1990-09-12 | 1998-05-26 | Bisgaard; Hans | Aerosol inhaler with piston dump |
| US6752147B1 (en) * | 1998-01-30 | 2004-06-22 | Hagepharm Gmbh | Inhalation apparatus for powder medications |
| CN1524001A (en) * | 2001-02-26 | 2004-08-25 | ���յ�ŵ˹��˾ | Nasal devices |
| CN110464922A (en) * | 2019-08-19 | 2019-11-19 | 丁瑞芬 | A kind of vaporizer dose control equipment |
| WO2021150883A1 (en) * | 2020-01-22 | 2021-07-29 | Virginia Commonwealth University | Air-jet dry power inhaler for rapid delivery of pharmaceutical aerosols to infants |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114768012A (en) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5320094A (en) | Method of administering insulin | |
| US6019100A (en) | Ventilator device | |
| RU2668067C9 (en) | Flow triggered pulsed oxygen delivery for medical applications | |
| KR20230136692A (en) | oxygen mask | |
| JP3258371B2 (en) | Device to transfer gas mixture to patient | |
| US5555890A (en) | Pharyngeal end-tidal carbon dioxide measuring catheter | |
| US3967619A (en) | Apparatus and method for intermittent mandatory ventilation | |
| CN114768012B (en) | Automatic quantitative drug delivery device for synchronous nasal cavity during exhalation | |
| CN210728587U (en) | Respiratory movement therapeutic device integrating respiratory training and inhalation drug therapy | |
| CN115282412B (en) | Drug delivery device for entering blood circulation through nasal cavity and application method thereof | |
| CN115282411A (en) | Delivery system for delivering drugs into the brain using the nasal olfactory region and method of use thereof | |
| CN105013054B (en) | A kind of more capsule dry-powder inhaling devices | |
| CN207768878U (en) | It is a kind of to treat pneumoconiosis oxygenation atomization suction apparatus | |
| CN104984449B (en) | A kind of capsule powder inhaler of turnable opening | |
| CN114470496B (en) | Nasal and olfactory region circulation drug delivery device | |
| CN202682489U (en) | Medical snuffle-type oxygen sucking tube | |
| CN205759100U (en) | A kind of disposable oxygen face mask | |
| CN209378230U (en) | Physiotherapy device for department of respiration | |
| CN217988110U (en) | Nasal catheter oxygen inhalation device capable of exhausting exhaled air flow | |
| CN204910374U (en) | Capsule dry powder type suction apparatus | |
| CN115300726A (en) | Special nasal delivery system and application method thereof | |
| CN213941779U (en) | Headrest type suspension anesthesia device for anesthesia department | |
| JP2005506136A (en) | Continuous gas leakage for elimination of ventilator dead space | |
| CN214485246U (en) | Medicine jet atomization inhalation device with double-channel T-shaped tube | |
| CA2540531A1 (en) | Device and method of partially separating gas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |